NCT00871546 2015-08-07
SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)
Merck Sharp & Dohme LLC
Phase 2 Terminated
Clinical Trials
6 trialsNCT00077961 2015-03-26
Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL
Sanofi
Phase 1/2 Terminated
NCT00051701 2015-03-05
Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma
Sanofi
Phase 1/2 Terminated
NCT00781781 2015-02-04
Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning
CABYC
Phase 2 Terminated
NCT00113048 2014-02-05
Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies
Sanofi
Phase 1 Terminated
NCT00836043 2013-12-03
Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia
Sanofi
Terminated